Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Cyclosporine vs Steroids in DRESS
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 50
- Registration Number
- NCT04988256
- Locations
- 🇺🇸
USC, Los Angeles, California, United States
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 102
- Registration Number
- NCT04979884
- Locations
- 🇪🇬
Alexandria university, Alexandria, Egypt
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Boston Sight
- Target Recruit Count
- 10
- Registration Number
- NCT04918823
- Locations
- 🇺🇸
BostonSight, Needham, Massachusetts, United States
Methods of T Cell Depletion Trial (MoTD)
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 400
- Registration Number
- NCT04888741
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, Wales, United Kingdom
Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Sight Sciences, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT04795752
- Locations
- 🇺🇸
Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Doctor My Eyes, Scottsdale, Arizona, United States
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04788641
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 32
- Registration Number
- NCT04781803
- Locations
- 🇲🇽
Hospital Universitario Dr. José E. González, Centro Universitario contra el Cáncer, Monterrey, Nuevo Leon, Mexico
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT04743739
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital， Capital Medical University, Beijing, Beijing, China
MSC for Treatment of cGVHD After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 152
- Registration Number
- NCT04692376
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.